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ABSTRACT 
Pancreatic beta cells within the islets of Langerhans contribute to the regulation of glucose 
homeostasis by secretion of insulin, a hormone that stimulates the uptake of glucose by liver, 
muscle and fat tissue. In response to variations in insulin demand, the beta cell population 
can adapt by (1) changing the total beta cell mass, and (2) modulating the functional capacity 
of individual beta cells. A failure of this mechanism will lead to disturbances in glucose 
homeostasis and the development of diabetes mellitus. A better understanding of the 
mechanisms underlying the regulation of a functional beta cell mass can help comprehend 
how diabetes develops and facilitate efforts to advance therapeutic strategies. 
Since quite some research has been performed on the regulation of beta cell mass, this thesis 
focused on elucidating mechanisms behind the functional adaptation of beta cells. The first 
part of the thesis describes the development of several tools to be able to study the beta cells 
in the context of the islet in vitro, and in vivo following transplantation into the anterior 
chamber of the mouse eye (ACE). Exploiting confocal microscopy and the intrinsic light 
scattering properties of islet cells, a label-free methodology was developed to describe the 
morphology and secretory status of the islets. This approach was utilised to quantify the islet 
volume and study islet mass kinetics in different mouse models of diabetes. Taking advantage 
of pseudoislets, a novel procedure was established to genetically engineer islets pre-
transplantation. It was shown that the synthetic modulation of an amplifying pathway in the 
beta cell could be used to regulate islet graft function, indicating that this technique is suitable 
to assess the role of specific proteins in beta cell function in vivo. 
In the second part, we researched how murine beta cells naturally regulate their function in 
vivo using a model of reduced beta cell mass. First, pancreatic beta cells were removed, 
leading to hyperglycaemia. Subsequently, glycaemia was normalised by transplanting a 
minimal number of islets into the ACE. This model enabled us to study the consequences of 
an increased workload on beta cells. It was found that long-term exposure to high workload 
leads to several functional adaptations in vivo as well as changes in the islet gene expression 
profile, thus indicating that beta cells can display functional plasticity under normoglycaemic 
and non-obese conditions. 
Our newly developed tools have broadened the possibilities to assess and enhance beta cell 
function in vivo, and helped to gain insights into the mechanisms regulating functional beta 
cell mass. Collectively, the technical advances and findings presented in this thesis could be 
used to improve diagnostics and therapeutics for diabetes.  
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1 INTRODUCTION 
1.1 GLUCOSE HOMEOSTASIS 
Maintaining a normal blood glucose homeostasis is essential for the function of all cells in 
our body and requires the interplay of several organ systems. Insulin and glucagon are the 
most important hormones to regulate blood glucose levels (glycaemia). The secretion of 
insulin and glucagon from the pancreas into the blood stream increases under relative 
hyperglycaemia and hypoglycaemia, respectively. Insulin stimulates the uptake of glucose 
by liver, muscle and fat tissue. Its function is counterbalanced by glucagon, which triggers 
the release of glucose from hepatic cells. 
1.1.1 Pancreatic islets 
The pancreas is a unique gland in the sense that it fulfils both an endocrine and an exocrine 
function. In mice, the gland can be subdivided into splenic, gastric and duodenal lobular 
compartments [1]. The majority of the pancreas consists of acinar cells that secrete digestive 
enzymes into the ducts leading towards the duodenum via the papilla of Vater. Only a small 
portion comprises of endocrine clusters called the islets of Langerhans or pancreatic islets. 
The islets have various sizes, ranging from 50 to 500 micrometres, and are found scattered 
throughout the pancreas (Figure 1). In the mouse pancreas, the larger islets seem to be 
arranged around the major blood vessels and ducts running from the splenic and gastric to 
duodenal lobe while smaller islets are mostly found in the periphery [2, 3]. 
 
Figure 1: Anatomy of the pancreatic islet. 
1.1.1.1 Islet cytoarchitecture 
Within the islet typically five highly specialised hormone-producing cell types are found: 
About 20-40 percent comprises glucagon-producing alpha cells, somatostatin-producing 
delta cells, pancreatic polypeptide-producing PP-cells, and ghrelin-producing epsilon-cells. 
The remainder are beta cells, responsible for the production and secretion of insulin [4, 5].  
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Beta cells use paracrine signalling to communicate with the other endocrine cells found in 
the islet. Importantly, human and rodent islets have somewhat different paracrine signalling 
pathways related to their cellular composition [6, 7]. Whereas in human islets beta cells are 
intermingled with the other endocrine cell types, rodent islets typically have a mantle of alpha 
and delta cells and a core of beta cells. It is not completely understood to what extent this 
affects islet cell function [6]. Interestingly, pseudoislets formed by spontaneous reassembly 
of dispersed rat islet cells were observed to have the same mantle-core structure found in 
intact islets [8], suggesting that individual cells within the pseudoislet can maintain the 
paracrine signalling that exists in intact islets. Jointly, these findings indicate that beta cell 
studies should preferentially be performed within the context of the intact islet or pseudoislet. 
1.1.1.2 Islet vascularisation and innervation 
Islet cells get their oxygen, nutrients (e.g. glucose), and hormones such as incretins from the 
same blood vessels that supply the exocrine pancreas. However, islets receive 5-15% of all 
the pancreatic blood flow despite comprising only 1-3% of the total pancreatic volume [9]. 
The intra-islet blood flow is regulated by nervous input and, in the case of rodents, involves 
both sympathetic and parasympathetic nerves. In addition, intra-islet hormones, connexin36 
and glucose levels have been shown to influence islet blood flow [10-13]. Interestingly, a 
recent report showed that blood flow is not affected by glucose concentrations in islets from 
non-human primates [14]. In mice, parasympathetic axons further influence beta cell function 
by secreting acetylcholine, a major neurotransmitter that acts on the muscarinic receptors of 
islet cells [15]. However, human islets have an innervation pattern consisting almost 
exclusively of sympathetic nerve fibres [16] and acetylcholine is instead produced by alpha 
cells [17]. Together, these studies demonstrate that islets require a dense network of 
vascularisation and innervation to facilitate a proper endocrine function. 
1.1.2 The beta cell  
Insulin is synthesised via its precursors preproinsulin and proinsulin, packaged as a hexamer 
with Ca2+ and Zn2+ ions, and stored in vesicles in the cytoplasm awaiting secretion [18]. The 
beta cell has a readily releasable pool of vesicles (1-5%) that provides an initial burst of 
secretion and can be followed by second phase insulin release of the subsequently recruited 
pool of secretory vesicles [19]. 
1.1.2.1 The role of the beta cell in glucose homeostasis 
Between glucose sensing and insulin secretion a cascade of events occur known as the 
triggering pathway (Figure 2) [20]. Extracellular glucose enters the beta cell via glucose 
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transporters (predominantly GLUT1 in human, GLUT2 in mouse) and is rapidly metabolised 
by glycokinase to generate ATP and pyruvate. In the mitochondria, pyruvate is processed 
resulting in increased NAD(P)H levels and the production of more ATP. A rise in 
cytoplasmic ATP levels consequently closes ATP-sensitive K+ channels (KATP), which leads 
to depolarisation of the cell membrane. In turn, this triggers the inflow of Ca2+ through 
voltage-dependent Ca2+ channels towards the cytoplasm. Additional Ca2+ is further mobilised 
from intracellular stores (i.e. the endoplasmic reticulum) mediated by 
inositol-1,4,5-trisphosphate (IP3). The increase in [Ca2+]i stimulates exocytosis of insulin-
containing vesicles [20-22]. The intracellular free Ca2+ ([Ca2+]i) oscillatory pattern in the beta 
cell is associated with the pulsatile secretion of insulin into the blood stream [23-25]. 
 
Figure 2: Intracellular signalling pathways in the pancreatic beta cell. 
In addition to glucose, several other nutrients (i.e. amino acids, free fatty acids) and non-
nutrient compounds (i.e. hormones and neurotransmitters) can modulate insulin secretion via 
G-protein coupled receptor (GPCR) amplifying pathways that affect the sensitivity of the 
secretory apparatus to [Ca2+]i [20]. Activation of Gs- and Gq-coupled GPCRs stimulates 
insulin secretion respectively via cyclic adenosine monophosphate (cAMP) mediated 
activation of protein kinase A (PKA) or phospholipase C activation of protein kinase C 
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(PKC). Inversely, activation of Gi-coupled receptors leads to decreased sensitivity of the 
secretory machinery to [Ca2+]i thus impeding insulin secretion [26]. 
Beta cells can function independently of their neighbours. However, studies on [Ca2+]i 
demonstrate a high synchronicity between beta cells within the same islet, indicating that 
individual cells preferentially work as part of a secretory unit together with the other beta 
cells. This functional syncytium has been attributed to cell-to-cell coupling via gap junction 
proteins, e.g. connexin36 [27, 28] and recently proposed to be coordinated by specialised hub 
cells [29]. While a synchronised [Ca2+]i pattern would suggest electrical coupling, non-
synchronised oscillations could indicate a lack of electrically coupled beta cells. Indeed, 
single cells obtained from islet dispersion show altered basal insulin release patterns 
compared to intact islets [30]. It can be concluded that an adequate electrical coupling 
between individual beta cells is necessary for a proper first and second phase insulin secretion 
as well as an intraislet [Ca2+]i synchronisation [27, 31].  
1.2 DIABETES MELLITUS  
1.2.1 Aetiology and epidemiology 
Under normal conditions, fasting glycaemia in humans ranges between 4 and 6 mM (and 
between 6 and 8 mM in mice depending on the strain). Failure of beta cells to produce and 
secrete sufficient insulin for the maintenance of adequate glucose levels leads to the 
development of diabetes mellitus (hereafter shortened to diabetes). The majority of cases of 
diabetes fall into two broad aetiopathogenetic categories, namely type 1 (T1D) and type 2 
diabetes (T2D). T2D comprises 90% of all cases while the other 10% is made up by T1D and 
less prevalent subtypes such as gestational diabetes [32]. Both T1D and T2D patients 
experience short- and long-term episodes of hyperglycaemia. Chronic hyperglycaemia can 
lead to microvascular and neural damage as well as kidney failure and other disorders [33]. 
The current prevalence of individuals with diabetes is estimated at 425 million worldwide, 
that is 8.8% of the population, and this number is expected to rise to 629 million (9.9%) in 
2045 [32]. Due to its continuously rising incidence, diabetes has a significant social and 
economic impact on our society.  
1.2.2 Clinical characteristics in humans and animal models 
1.2.2.1 Type 1 diabetes 
T1D is an autoimmune disorder that predominantly presents itself during childhood and is 
therefore also referred to as juvenile diabetes. Insulitis, i.e. the lymphocytic infiltration into 
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the islet, leads to a gradual beta cell destruction. Upon the emergence of hyperglycaemia, 
individuals may have already lost 40-85% of their beta cells depending on their age [34] 
whereas at later stages only a few percents are detected [35]. The prevalence of T1D varies 
dramatically between countries, strengthening the idea that the susceptibility depends on a 
certain genetic predisposition [36]. Although the role of genetics in the aetiology of T1D is 
important, an additional environmental trigger is thought to be required to initiate the process 
of insulitis [37, 38]. Over the past decades a large number of environmental factors have been 
found to be associated with the development of T1D, including several viruses [39] and 
changes in gut microbiota and permeability [40]. 
Animal models have been crucial in obtaining mechanistic data on the pathogenesis of 
diabetes [41]. The non-obese diabetic (NOD) mouse and the Biobreeding rat represent two 
of the most common models for T1D. These rodents spontaneously develop insulitis during 
the first few weeks after birth, often resulting in diabetes [42-44]. Chemical ablation of beta 
cells is another common method to induce a diabetic phenotype. It comes with the advantage 
that beta cell destruction can be initiated at any desired time point during the lifespan of the 
animal. For instance, administration of streptozotocin, a ligand of the glucose transporter, 
causes beta cell death in a dose-dependent fashion through alkylation and subsequent necrosis 
[45]. In addition, genetically modified mouse models can be used. For example, diphtheria 
toxin (DT) treatment of mice carrying the DT receptor on their beta cells enables selective 
beta cell destruction [46]. DT facilitates the inhibition of elongation factor 2, resulting in the 
inhibition of protein synthesis and ultimately cell death [47].  
1.2.2.2 Type 2 diabetes 
T2D is a complex and multifactorial disease that is often associated with obesity [48]. Many 
genetic mutations and environmental factors have been discovered to trigger diabetes as well 
as obesity. Impaired glucose tolerance due to decreased insulin sensitivity in tissues such as 
the liver, muscle and fat hallmarks the progression towards T2D. Human T2D subjects 
display an inability to rapidly release insulin after a meal, causing spikes in blood glucose 
values. To counter the decreased insulin sensitivity, beta cells hypersecrete insulin, 
progressively creating a hyperglycaemic and hyperinsulinaemic milieu [48, 49]. In long-
standing T2D, factors including glucotoxicity and lipotoxicity lead to beta cell failure. The 
increased frequency of beta cell apoptosis observed in the pancreas of T2D subjects [50] 
explains why their beta cell number is, on average, found to be two-thirds less compared to 
healthy subjects [51, 52]. 
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To mimic T2D phenotypes such as obesity and insulin resistance, researchers frequently use 
dietary models [53]. For instance, high-fat feeding is a practical means to increase calorie 
intake for a particular period of time and can be applied to rodents or other animal models. 
Alternatively, several rodent models exist that display chronic overeating due to a deficiency 
in leptin signalling: The ob/ob and db/db mice bear a mutation in the leptin protein and 
receptor, respectively [54, 55]. The Zucker Diabetic Fatty rat also has a mutation in the gene 
encoding for the leptin receptor [56]. An example of a non-obese yet glucose intolerant 
animal is the Goto-Kakizaki rat [57].  
1.2.3 Clinical and experimental treatments 
The goal of any diabetes treatment is not only to improve glucose homeostasis, but also to 
prevent or delay any possible complications that result from an imbalance in glycaemia. For 
the past century the substitution of insulin, either via subcutaneous injections or using an 
insulin pump, has been the primary choice of therapy for all individuals diagnosed with T1D. 
Alternatively, methods are being developed for oral, transdermal, intranasal, and inhalable 
administration of insulin [58]. Rather than only improving the lack of insulin (insulinocentric 
view), Unger and others have proposed a glucagonocentric view in which a dampening of 
the excess glucagon would decrease glucose release by the liver amongst other effects [59]. 
Although insulin supplementation is also common for individuals with T2D, the focus is 
often on dietary changes and lifestyle interventions. In addition, pharmacological treatments 
such as metformin, sulfonylureas and GLP-1 analogues are prescribed. The former decreases 
hepatic glucose release whereas the latter two enhance endogenous insulin secretion [60]. 
1.2.3.1 Beta cell regeneration and replacement strategies 
Since no method of insulin delivery matches the capacity of the beta cells to maintain blood 
glucose levels within a strict range, several strategies are explored to replace the lost beta 
cells [61]. One option that is currently looked into is to regenerate existing beta cells, either 
through controlled proliferation or by reprogramming of exocrine and/or other islet cells into 
beta cells [62, 63]. 
Transplantation of the whole pancreas and of isolated pancreatic islets, obtained from 
deceased organ donors, have been successful in decreasing or sometimes even completely 
abolishing insulin dependence in T1D subjects [64, 65]. Despite the promising results, this 
option requires a life-time treatment with immunosuppressive drugs and is limited by the 
availability of donor organs [64]. The use of stem or progenitor cells would be a solution to 
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the limited supply of donor tissue. Significant scientific progress has recently been made in 
the field of stem cell transplantation [66] and the growth of new beta cells from progenitor 
cells [67].  
1.2.3.2 Islet transplantation 
The vast majority of islet transplantations performed in a clinical setting involve the 
intrahepatic infusion of islets via the portal vein. Because the liver may not provide the islets 
with the optimal conditions required for survival, multiple alternative sites have been 
evaluated in both experimental and clinical studies of islet transplantation [68, 69]. 
Considerations when selecting a transplantation site include the accessibility, survival of the 
graft, and drainage of the secreted insulin to the target organs. In most rodent studies, islets 
are transplanted beneath the renal capsule, where they form an aggregated islet cell pellet. 
Alternatively, islets can be transplanted in locations where they engraft as individual islets, 
such as intraportally into the liver [70] or into the anterior chamber of the eye (ACE) [71]. 
The isolation procedure disrupts the islet from vessels and nerves, connections that need to 
be re-established following transplantation during the engraftment process. Depending on the 
transplantation site, revascularisation of rodent islets is initiated 1-3 days and completed 2-4 
weeks post-transplantation [70-72]. Longitudinal imaging of autologous islet grafts in the 
ACE of primates demonstrated that in this more human-like setting revascularisation is 
initiated within 4-10 days and completed circa 90 days following transplantation [14]. 
Furthermore, mouse islets transplanted into the ACE were found to be reinnervated within 
circa one month [15]. The revascularisation process involves the ingrowth of endothelial cells 
from the host as well as outgrowth of intra-islet endothelial cells, provided the islets are 
freshly isolated, and is mediated by vascular endothelial growth factors (VEGF) [73-75]. 
Vessel remodelling and maturation occur to ensure a dense and functional vascular network 
in the islet graft, similar to that of in situ islets [70].  
Although little is known about the engraftment efficiency of clinically transplanted islets, 
reports on human islets infused into the liver or placed under the kidney capsule of nude mice 
indicate that 50-70% of the islets are lost in the post-transplantation period. Moreover, the 
vascular density in these human islet grafts is lower than in endogenous islets [76-78].  
1.3 REGULATION OF BETA CELL MASS AND FUNCTION 
Two frequently used parameters in diabetes research are beta cell mass and beta cell function. 
The term beta cell mass refers to the total amount of beta cells (number or volume) in the 
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organism. Although the exact definition of beta cell function is more elusive, this parameter 
commonly describes the capacity of individual cells to secrete insulin in response to a 
triggering signal. In a pathological context, the opposite term beta cell dysfunction is used. 
A complete lack of beta cell function is referred to as beta cell failure. In principle, a defect 
in any of the components required for glucose sensing and insulin secretion can lead to beta 
cell dysfunction or failure.  
The collective term functional beta cell mass thus refers to the insulin producing cells within 
the organism that contribute to the regulation of glucose homeostasis. Figure 3 illustrates 
how a change in functional beta cell mass in an example of diabetes progression results in 
hyperglycaemia. 
 
Figure 3: Relationship between functional beta cell mass and glucose homeostasis. 
1.3.1 Regulation of beta cell mass 
In mammals, beta cell mass is maintained by the careful balance of cell expansion and 
renewal (through replication or neogenesis), and cell loss (via apoptosis or autophagy) [79, 
80]. Under normal physiological circumstances the rate of beta cell turnover and apoptosis 
are slow. An assessment of human beta cell replication pre- and postnatally indicates that 
proliferation is relatively high around the time of birth (0.5-5.0%) but remains low from six 
months onwards (0.1%) [81]. Similar or slightly higher numbers were found in rodents [82, 
83]. Apoptosis that could occur during diabetes causes an imbalance that results in a shortage 
of beta cells. 
Beta cell mass is dynamically regulated by certain physiological and pathophysiological cues 
related to changes in insulin demand [61, 84]. An adaptive beta cell mass expansion has been 
Functional beta cell mass 
Normoglycaemia 
Hyperglycaemia 
Glycaemia 
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found using rodent models of obesity and T2D [85-87], T1D [88], pregnancy [80] and beta 
cell loss or damage (e.g. partial pancreatectomy) [89-91]. Obesity was also associated with a 
higher beta cell turnover in human pancreas samples [92]. In contrast, no increased 
proliferation could be detected in the beta cells from individuals with T2D having impaired 
fasting glucose [92], recently diagnosed T1D patients [93] and subjects that previously 
underwent partial pancreatectomy [94]. It has been proposed that the proliferative capacity 
of the beta cell is to some extent restricted by age [95, 96]. Since most rodents studies are 
performed with relatively young animals, these results may not be comparable to the human 
pancreas [96, 97]. Moreover, neogenesis from non-endocrine pancreatic cells, and not 
proliferation, seems to be the dominant mechanism of adaptive beta cell growth in humans 
[98]. 
Glucose is thought to be the main cue involved in the regulation of beta cell mass. Systemic 
infusion of glucose markedly increased beta cell growth, while dampening glucose levels by 
insulin infusion had the opposite effect [99-101]. A recent study suggests that glucose is able 
to induce proliferation of beta cells via mTOR and ERK activation [102]. Other components 
essential for proliferation include glucokinase, KATP channels, Beta-arrestin-2, cyclin D2, 
FoxM1, Beta2/neuroD, PDX-1 and insulin receptor substrate 2 [101-105]. During pregnancy, 
lactogenic hormones can modulate the local levels of menin and serotonin to increase beta 
cell proliferation [106, 107]. 
1.3.2 Regulation of beta cell function 
The regulation of beta cell function also occurs in a dynamic fashion. Individual beta cells 
can modulate their function in terms of insulin production/secretion or altered responsiveness 
during (patho)physiological conditions such as those described above [108]. For instance, the 
evolution of T1D may involve a period of remission during which patients require smaller 
doses of exogenous insulin owing to increased endogenous insulin secretion. This so called 
“honeymoon phase” is commonly presented a few months or years after diagnosis [109].  
1.3.2.1 Beta cell heterogeneity 
Studies on partial pancreatectomy and the pancreas of T1D subjects upon diagnosis show 
that a loss of up to ~80% of the total beta cell mass does not lead to hyperglycaemia [34, 90, 
110, 111], indicating that rodents and humans have an enormous overcapacity in terms of 
functional beta cell mass. It further implies that beta cell function is heterogeneous [112], and 
that a certain proportion of islet cells has a low functional status (i.e. dormant or in a different 
stage of their life cycle) that could be triggered under higher demands.  
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Beta cell heterogeneity has been demonstrated from various angles including glucose-
responsiveness, insulin promotor activity, insulin protein levels (reviewed in [113]), 
endoplasmic reticulum content, number of secretory granules, size of the beta cell nucleus 
(reviewed in [114]), overall beta cell size [115], insulin secretion [116], and Ca2+ oscillations 
[117]. Using electron microscopy it was shown that, compared to beta cells in the periphery 
of the rat islet, beta cells in the core are more degranulated after glucose stimulation [118]. 
The recent discoveries of several subpopulations of beta cells based on next generation 
sequencing experiments have confirmed the concept of a heterogeneous beta cell population 
[119-121]. 
Variations in function have not only been demonstrated between individual beta cells but 
also between individual islets within the pancreas after glucose stimulation [118] or high-fat 
diet (HFD) [122]. Differences in blood perfusion could be an underlying explanation of such 
beta cell heterogeneity [123]. 
1.3.2.2 Animal studies on functional beta cell adaptation 
Not much is known about functional plasticity in human beta cells. Most of the current 
knowledge comes from studies on animals, predominantly rodent models of insulin 
resistance and obesity. Alternatively, models of pregnancy and decreased beta cell mass, e.g. 
partial pancreatectomy, have been explored. In the following section, the observations from 
some key animal studies are briefly discussed in order to obtain an overview of phenotypical 
changes naturally occurring in rodent beta cells. 
In studies of HFD, mice gradually become obese. Gonzalez et al. [115] demonstrate that this 
does not only lead to compensatory beta cell proliferation, but also to functional adaptations. 
Using islets isolated from female mice fed a HFD for 12 weeks they found that beta cells 
displayed hypertrophy, contained more insulin and exhibited increased [Ca2+]i signalling and 
insulin secretion upon glucose stimulation compared to beta cells from mice on control diet. 
In addition, islets from mice exposed to HFD contained a greater number of glucose 
responsive beta cells and, likely due to their increased size, the number of exocytotic events 
per beta cell was higher. In contrast, Chen and co-workers [124] could show an increased 
basal and blunted glucose-stimulated [Ca2+]i amplitude in beta cells after 8 and 16 weeks of 
HFD using an in vivo microscopy approach. Moreover, in their model an increase in islet size 
could not be explained by beta cell hypertrophy. By repeated in vivo imaging of the same 
islet it was found that HFD feeding led to a transient degranulation and a minimal but 
significant widening of the intraislet vessel diameter.  
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Beta cells in obesity models such as the ob/ob and db/db mice also seem to display functional 
changes during the first weeks after birth. Islets isolated from the ob/ob and prediabetic db/db 
mouse were observed to have a higher insulin content due to augmented insulin biosynthesis, 
and increased glucose-induced insulin secretion [125-127]. Compared to controls, beta cells 
in these islets exhibited changes in their [Ca2+]i pattern under relatively low glucose levels 
(<8.0 mM), suggestive of enhanced glucose sensitivity [125, 126]. Furthermore, in islets from 
ob/ob mice an improved Ca2+ mobilisation, increased mitochondrial activity [125], beta cell 
hypertrophy and blood vessel dilation were observed [86]. Yet, these alterations were 
paralleled by beta cell uncoupling and worsened glucose clearance in vivo [86, 125].  
However, not all animal models of obesity/diabetes are suitable to investigate functional beta 
cell plasticity. In the Zucker fatty and Zucker diabetic rat models for example, some studies 
show functional compensatory mechanisms within islets such as hypersecretion of insulin 
and upregulated glucose metabolism [128, 129], while others only report changes in beta cell 
mass and not in function [130].   
In studies of decreased beta cell mass an improvement in individual beta cell function could 
be observed. Islets remaining after 60% and 90% pancreatectomy outperformed control islets 
from sham-operated rats in terms of insulin secretion and glucose utilisation, and had a lower 
sensitivity threshold for glucose through a mechanism involving increased glycolytic activity 
and glucokinase levels [131-133]. 
Finally, changes in beta cell function are seen in the early stages of pregnancy. Islets isolated 
from pregnant mice or treated for 4 days with prolactin in vitro (to simulate pregnancy) 
exhibited a lower glucose sensitivity threshold, improved insulin secretion and beta cell 
coupling, islet cell hypertrophy and upregulated insulin biosynthesis [134-136].  
Together, these studies indicate that rodent beta cells can exploit several adaptive 
mechanisms. It remains elusive how many independent mechanisms are involved in the 
regulation of a functional beta cell mass. It is conceivable that different (patho)physiological 
cues have their own pathways and are thus unrelated processes operating in parallel. To what 
extent the mechanisms found in rodents can be translated to human is an ongoing debate.  
A better understanding of the adaptive mechanisms in the beta cell can (1) facilitate efforts 
to expand beta cells and enhance their functional capacity in vitro; (2) advance therapeutic 
options in vivo, e.g. the identification of small molecules to target beta cell specific pathways; 
and (3) help comprehend how diabetes develops due to a failure in these mechanisms.  
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1.4 IMAGING OF BETA CELL MASS AND FUNCTION 
Beta cell mass and beta cell function are relevant biomarkers for the staging and diagnosis of 
diabetes, or to evaluate treatments [34, 137, 138]. Because the size of the beta cell population 
is controlled via a feedback loop that is directly coupled to its function, the two parameters 
are sometimes used to describe or predict each other [139-144]. 
1.4.1 In vitro and ex vivo methods to study beta cell mass and function 
Historically, beta cell mass assessment has been limited to quantification of the pancreatic 
insulin content and insulin-labelled area in sliced pancreatic tissue. The development of 
optical projection tomography (OPT) for whole pancreatic samples for the first time provided 
stereological information to in depth describe islet distribution throughout the organ and 
analyse the total beta cell volume [145]. A clear drawback of these ex vivo approaches is that 
experimental assessment of beta cell mass kinetics required many animals. 
Although repeated measurements of beta cell function can be performed in vivo (e.g. 
intravenous or oral glucose tolerance test and hyperglycaemic clamp), these only reflect the 
situation in the entire beta cell population and not individual cells or islets. Insulin release 
can however be studied from individual or groups of isolated islets or (beta) cells in vitro, 
but this will deprive them from their natural microenvironment and many circulating factors. 
Nevertheless, most of our current knowledge on islet function comes from studying isolated 
islets. 
1.4.1.1 Fluorescent biosensors for imaging of islet function 
A range of fluorescent biosensors has been developed to study several of the steps involved 
in glucose-induced insulin release [146]. As such, glucose uptake kinetics could be monitored 
by fluorescent glucose analogues [147]. Changes in [Ca2+] in various intracellular cell 
compartments were recorded by a number of  fluorescent indicators and genetically encoded 
probes [148, 149]. Further, exocytotic events have been visualised using Zn2+ which is co-
released with insulin or a pH-sensitive probe that reflects changes occurring upon granule 
fusion [150-152]. Of these, [Ca2+]i has by far been the most commonly used read-out. 
1.4.2 In vivo imaging of beta cell mass and function  
Recent advances in the field of intravital imaging, such as the development of novel tracers 
as well as functional and molecular imaging methods, have opened new opportunities to 
study beta cell mass and function in a clinical or pre-clinical setting [138, 153]. Two broad 
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types of modalities can be distinguished to image the beta cell in vivo: optical and non-optical 
imaging. 
Non-optical imaging modalities including magnetic resonance imaging (MRI), positron 
emission tomography (PET), and single-photon emission computed tomography (SPECT) 
are already available in a clinical setting and therefore represent the preferred screening 
platform for humans. While the research field has mainly focused on the quantification of 
beta cell mass, either in the pancreas or from transplanted islets, some possible functional 
compounds have been proposed as well. For instance, MRI enhanced manganese imaging 
has been used for studies of beta cell mass but since it accumulates in glucose-activated beta 
cells proportionally to the glucose concentration, it could also be used as a functional 
biomarker for MRI [154].  
Optical imaging techniques such as bioluminescence imaging, confocal laser scanning 
microscopy (LSM) and optical coherence microscopy (OCM) have been employed in 
experimental settings for imaging of pancreatic beta cell mass [155-157] and blood flow [158, 
159]. However, confocal LSM and OCM required laparotomy and exteriorisation of the 
pancreas due to the limited optical accessibility of the islets, hence hampering repeated 
assessment. Instead, body windows have been suggested as a possible solution [160, 161]. 
1.4.2.1 Imaging of islets transplanted into the anterior chamber of the eye 
In 2008, a novel in vivo imaging platform was presented that combined islets transplanted 
into the anterior chamber of the mouse eye with LSM [71]. Ingeniously, the cornea was used 
as a natural body window to visualise islets engrafted onto the iris. As a result, the high 
resolution of confocal microscopy could be exploited to study cellular events within islet 
cells in the living mouse or rat. Importantly, it was shown that islet grafts in the ACE could 
directly report on the status of the endocrine pancreas [86]. 
During the last decade, the ACE platform has been exploited for a number of studies on beta 
cell mass and function, as recently reviewed [162]. For instance, the progressive growth of 
islets in the ob/ob mouse and the gradual destruction of islet cells in the NOD mouse could 
be monitored in detail [86, 163]. Furthermore, several parameters of islet function have been 
studied. For example, ratiometric imaging of NAD(P)H and FAD autofluorescence was used 
to detect increased mitochondrial metabolism [164] and high speed recording of the biosensor 
GCaMP3 in a single confocal plane was performed to show changes in the beta cell [Ca2+]i 
pattern [124]. 
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Intraocular imaging of islets is not limited to confocal LSM. In 2016, the group of Prof. 
Lasser successfully applied OCM to islets transplanted into the ACE and demonstrated the 
usefulness of this technique for label-free investigation of the dynamics of individual islet 
mass and vessel density as well as blood flow [159]. Also, Nord et al. used vibrational 
microspectroscopy for the imaging of biochemical compounds from islets in the ACE [165]. 
The ACE platform thus enables real-time monitoring of islet grafts in response to external 
stimuli (e.g. glucose) and assessment of the same islet over time in great detail, rendering it 
the perfect tool to study the dynamics of beta cell function. 
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2 AIMS 
Exploiting the recent progress in the field of intravital imaging, the general aim of this thesis 
was to investigate how beta cell function is regulated in vivo.  
The first part of this work focuses on the establishment of several tools to study beta cell 
function. The following aims are defined:  
• Development of an imaging method to study beta cell mass and function in vivo 
• Generation and characterisation of a mouse model of minimal beta cell mass 
• Development of an in vivo approach to assess the role of specific genes for beta cell 
function  
In the second part, the mouse model of minimal beta cell mass is exploited to accomplish the 
following aims: 
• Investigation of changes in beta cell function in vivo  
• Identification of genes involved in the natural regulation of beta cell function 
  
 16 
3 MATERIALS AND METHODS 
3.1 MATERIALS 
All materials were from Sigma, unless specified otherwise. 
3.1.1 Solutions and buffers 
Buffered solution used for perifusion and batch incubation experiments contained 125 mM 
NaCl, 5.9 mM KCl, 2.6 mM CaCl2, 1.2 mM MgCl2, 25 mM HEPES (pH 7.4) and 0.1% 
bovine serum albumin (BSA). TBST contained 0.15 M NaCl, 0.1 M Tris pH 7.5, 0.1-0.3% 
Triton X-100. Blocking buffer was based on TBST or PBS supplemented with 10% goat 
serum and 0.01% sodium azide. Hank’s balanced salt solution (HBSS) was buffered with 
HEPES (pH 7.4) and supplemented with 1 mg/ml Collagenase A or P for islet isolation, or 
instead 0.5% bovine serum albumin for washing and hand-picking. Islet cell lysis buffer 
contained DEPC-treated water (Thermo Fisher Scientific), 0.2% Triton-X and 5% 
RNAseOUT (Thermo Fisher Scientific). 
3.1.2 Culture media 
RPMI-1640 was supplemented with 2 mM L-Glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin, and 10% fetal bovine serum. CMRL-1066 (ICN Biomedicals) was 
supplemented with 10 mM HEPES, 2 mM L-Glutamine, 0.25 mg/ml Fungizone, 50 mg/ml 
Gentamycin, 20 mg/ml Ciprofloxacin, 10 mM Nicotinamide and 10% fetal bovine serum. 
3.1.3 Fixatives 
Fresh paraformaldehyde (PFA) was prepared by dissolving 4 g in 90 ml dH2O with a 
temperature of >65°C following the addition of 25 µl 5 M NaOH. The cooled-down mixture 
was supplemented with 10 ml of 10x PBS and filtered. For transmission electron microscopy, 
a fixative was used containing 2.5% glutaraldehyde + 1% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4). Post-fixation was done with 2% osmium tetroxide in 0.1 M 
phosphate buffer (pH 7.4). 
3.2 ANIMAL MODELS 
All animals were housed in Karolinska Institutet’s animal core facilities in a temperature (22 
± 2°C) and humidity controlled room with a 12-hour light/12-hour dark cycle. Animals had 
access to water and standard rodent chow diet. Animal experiments were performed in 
accordance with Karolinska Institutet’s guidelines for care and use of animals in research and 
approved by the animal ethics committee at Karolinska Institutet. 
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C57BL/6J mice, SJL mice and Wistar rats were purchased from Charles River Laboratories 
(Germany). MIP-GFP mice, ob/ob (Lepob/Lepob), and Ins-GCaMP3 mice were inbred at the 
animal core facility on a C57BL/6J background for at least 10 generations. RIP-DTR mice 
expressing diphtheria toxin receptors (DTR) on their beta cells [46] were kept on a mixed 
background or backcrossed one generation on a C57BL/6J background. MIP-GFP mice 
express green fluorescent protein (GFP) in their beta cells [166]. The ob/ob colony originates 
from Umeå, Sweden, and was shown to be insulin resistant between the age of 2 and 7 months 
[167]. Ins-GCaMP3 mice were generated by crossing heterozygous B6(Cg)-Instm1.1(cre)Thor/J 
mice [168] and B6;129S-Gt(Rosa)26Sortm38(CAG-GCaMP3)Hze/J mice [169]. Ins-GCaMP3 mice 
express the genetically encoded Ca2+ sensitive biosensor GCaMP3 in their beta cells enabling 
fluctuations in [Ca2+]i to be monitored by changes in fluorescence intensity [170]. 
3.3 METABOLIC TESTS AND TREATMENTS 
3.3.1 Glucose and insulin measurements 
Blood glucose concentrations in mice were obtained by measuring a drop of blood from the 
tail vein with a Accu-Chek Aviva system (Roche), which allows readings up to a maximum 
of 35.0 mM. Higher values were considered 35.0 mM. Plasma was obtained by collection of 
blood via the tail vein in EDTA coated micro-cuvettes following centrifugation at circa 1000 
g for at least 10 minutes at 4°C. Plasma was stored at -20°C pending insulin content analysis 
with AlphaLISA (Perkin Elmer) according to the manufacturer’s instructions in duplicate or 
triplicate. For pancreatic insulin content measurements, the pancreas was collected in ice cold 
PBS, weighed, transferred to 1.4 ml of ice cold acid ethanol (75% ethanol, 0.2 M HCl), 
homogenised with a handheld tissue homogeniser and stored at -20°C. On the day of analysis, 
a probe-sonicator was used for further cell lysis prior to measurement with ultrasensitive 
mouse insulin enzyme-linked assay (ELISA) kit (Crystal Chem Inc.) in duplicate. 
3.3.2 Glucose and insulin tolerance tests 
Prior to glucose and insulin tolerance test (GTT or ITT), animals were fasted overnight (12 
hours), in the morning (6 hours) or used unfasted as indicated. For a GTT, mice received an 
intraperitoneal injection of 2 g glucose per kg bodyweight. For an ITT, mice received 0.5 U 
insulin per kg bodyweight by intraperitoneal injection. Glycemia was measured at fixed time 
points up to 150 minutes, as indicated. 
3.3.3 Streptozotocin and diphtheria toxin treatments 
Streptozotocin (STZ) was freshly dissolved in citric acid buffer (pH 4.5) and administered 
by a single intraperitoneal injection to male 8-10-week-old mice following 4-6 hours fasting. 
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Depending on the experiment, a dose between 150 and 250 mg per kg bodyweight was used. 
Diphtheria toxin (DT) was stored at -80°C at a stock concentration of 2 mg per ml dH2O. 
Animals received 500 ng DT via a single intraperitoneal injection regardless of their body 
weight. 
3.4 IMMUNOHISTOCHEMICAL AND STRUCTURAL ASSESSMENT 
Antibodies were diluted in blocking buffer. Incubation steps for blocking and primary 
antibody staining were 1 hour for sections, 24 hours for islet grafts and 48 hours for whole 
pancreas specimens. Secondary antibodies incubation steps were overnight for sections and 
24-48 hours for whole mounts. 
3.4.1 Paraffin sections 
Tissues were dissected and rinsed with PBS following fixation with formalin for 48 hours at 
room temperature. Dehydrated tissue was embedded in paraffin and sectioned at 5 µm 
thickness by a shared facility at Karolinska Institutet. Dewaxed, rehydrated tissues were 
stained with haematoxylin and eosin, or blocked and insulin-labelled with chicken anti-
insulin (1:200 dilution, Abcam) followed by goat anti-chicken Alexa Fluor 488 (1:1,000 
dilution, Invitrogen) or guinea pig anti-insulin (1:1,000 dilution, DAKO A0564, Agilent 
Technologies) followed by goat anti-guinea pig Alexa Fluor 488 (1:1,000 dilution, Thermo 
Fisher Scientific). Nuclei were stained upon mounting using ProLong Gold Antifade Reagent 
with DAPI (Invitrogen). Images were acquired using a BD Pathway 855 system (BD 
Biosciences). 
3.4.2 Frozen sections and whole mounts 
Tissues were dissected in PBS, fixed in 4% PFA on ice for 2-3 hours, rinsed in PBS and 
placed in 30% sucrose solution overnight. For frozen sections, tissues were embedded in 
Optimal Cutting Temperature compound and sliced at 10 µm thickness. After blocking, the 
following primary and secondary antibodies were used in 1:1,000 dilution on sections or 
whole mount grafts to label insulin, glucagon or StrepTag II: guinea pig anti-insulin (DAKO), 
mouse anti-glucagon antibodies (Sigma G2654), mouse anti-Strep-tag II (Qiagen), goat anti-
guinea pig Alexa Fluor 488, and goat anti-mouse Alexa Fluor 594 or 633 (Thermo Fisher 
Scientific). Frozen sections were further mounted with ProLong Gold Antifade with DAPI. 
Images were acquired using a Leica SP5 system. 
For optical projection tomography, connective tissue membranes and lymph nodes were 
removed. Fixed tissues were dehydrated (stepwise) to 100% MeOH, exposed to at least five 
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freeze/thaw cycles at -80°C to facilitate antibody penetration, and bleached overnight in a 
mixture of MeOH (Thermo Fisher Scientific), DMSO and 15% H2O2 at a 2:3:1 ratio to reduce 
endogenous tissue fluorescence. Tissues were rehydrated back to TBST (stepwise), blocked, 
and stained with anti-insulin primary antibody (1:500 dilution, DAKO) and a secondary goat 
anti-guinea pig Alexa Fluor 594 (1:500 dilution). Each pancreas was divided into a splenic, 
gastric and duodenal lobe, which were separately embedded in a filtered low-melting agarose 
gel. Samples were cleared by submersion in a 1:2 mixture of benzyl alcohol (Scharlab) and 
benzyl benzoate (Acros Organics), three washes in total. Samples were slowly rotated and 
sequentially excited at 488 and 594 nm to visualise anatomy and insulin positive signal, 
respectively (Figure 4). A series of 800 projection images was acquired with a Bioptonics 
3001 OPT scanner (SkyScan). A video protocol is available [171]. 
 
Figure 4: Schematic representation of a sample scanned by optical projection tomography. 
Adapted from Sharpe et al. [172]. 
3.4.3 Dead cells labelling 
Islet cell death was assessed using an apoptosis kit (V13240, Invitrogen) following the 
manufacturer’s instructions. Confocal images of dead cells within intact islets were acquired 
using a Leica SP5 confocal system. 
3.4.4 Transmission electron microscopy 
Small pieces of pancreas, isolated islets or whole islet grafts were pre-fixed at room 
temperature for 30 min and stored in fixative at 4°C. Subsequently, tissues were rinsed in 0.1 
M phosphate buffer and post-fixed at 4 °C for two hours, dehydrated in ethanol followed by 
acetone and embedded in LX-112 (Ladd). Tissue processing, sectioning and transmission 
electron microscopy imaging were performed by the shared facility.  
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3.4.5 Zinc chelation and dithizone staining 
Isolated islets were treated with 25 µM N,N,N',N'-tetrakis-(2 pyridylmethyl)ethylenediamine 
(TPEN) for 8 hours to remove intracellular Zn2+. Treated islets were studied by reflected light 
imaging on a Leica SP5, stained with dithizone and imaged with a light microscope, or 
collected for transmission electron microscopy. 
3.5 ISLET ISOLATION, PSEUDOISLET FORMATION AND TRANSDUCTION 
3.5.1 Islet isolation 
Mouse islets were obtained from both males and females aged between 2 and 8 months. Mice 
were sacrificed by cervical dislocation and sterilised with 70% ethanol. The abdominal 
organs were exposed by a V-section and the sternum and diaphragm were cut. The liver was 
tilted backwards and the intestines were placed outside of the abdominal cavity to expose the 
bile duct. The duodenal papilla was clamped with a bulldog clamp to prevent leakage into 
the duodenum. Next, the bile duct was cannulated with a 27-30 G needle attached to a 
polyethylene tubing and 2-3 ml of cold collagenase was slowly infused into the pancreas via 
the bile duct. If cannulation was unsuccessful the pancreas was cut in 1 mm3 pieces. Excised 
tissue was placed in 2 ml additional collagenase solution. Enzymatic digestion was initiated 
by incubation at 37°C in a water bath and terminated by the addition of ice cold HBSS after 
10-12 minutes. The digest was carefully disrupted using 18-22 G needles. Following three 
washes, islets were handpicked in non-adherent tissue culture dishes. Rat islets were prepared 
using similar methods. Islets were directly collected for RNA or protein extraction, or 
cultured in RPMI in a humidified atmosphere with 5% CO2 at 37C.  
Human islets were obtained via the Nordic Network for Islet Transplantation, procured from 
deceased organ donors by established procedures [173], and cultured in CMRL. 
3.5.2 Pseudoislet formation 
Islets were dissociated into single cells by enzymatic digestion for 10 min at 37°C using 
Accutase followed by up and down pipetting to disrupt cell clusters. Cell numbers were 
determined using a TC20 automated cell counter (Bio-Rad). Droplets of 40 µl containing 
62,500 cells per ml in cell culture medium were placed in each well of a 96-well 
GravityPLUS hanging drop system plate (Perkin Elmer). Pseudoislets were formed and 
collected after 6-7 days following the manufacturer’s instructions.  
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3.5.3 Viral transduction 
Islet cells were transduced with the adenoviruses RIP1-hV1BR, containing the coding 
sequence of the human V1b receptor together with a Strep-tag II label, and RIP1-R-GECO1, 
encoding for the red calcium indicator R-GECO1 [149]. Viruses were purified and 
concentrated using Fast-Trap (Millipore), following the manufacturer’s instructions. Intact 
islets or a suspension of islet cells were transduced in the hanging droplet in the presence of 
0.2, 1, 5 or 25 thousand viral particles per µl. 
3.6 IN VITRO AND EX VIVO FUNCTIONAL EXPERIMENTS ON ISLETS 
3.6.1 Measurements of intracellular Ca2+ 
Intracellular free Ca2+ recordings were carried out with Fura-2/acetoxymethyl ester (Fura-
2/AM) loaded islets that were either cultured overnight or freshly micro-dissected from the 
eye. Fura-2/AM is a ratiometric fluorescent Ca2+ indicator which is highly cell membrane 
permeable due to its lipophilic properties. Inside the cell, the cleavage of the acetoxymethyl 
ester traps Fura-2 inside the cytoplasm. Upon binding of Ca2+ to Fura-2, the molecule 
undergoes an absorption shift to shorter wavelengths. Alternating excitation between 340 and 
380 nm allows the measurement of calcium bound and calcium free forms of Fura-2, 
respectively [174]. Islets were incubated for 1 hour with 2 µM Fura-2/AM in buffered 
solution with 3 mM glucose, mounted on a coverslip with Puramatrix Hydrogel (BD 
Biosystem), and perifused with various buffered solutions at 37°C. Perifusion buffer was 
supplemented with 3, 11 or 15 mM glucose, 25 mM KCl, and/or 100 nM [Arg8]-vasopressin 
(AVP). Following excitation at 340 and 380 nm, fluorescence was collected using a 510/40 
nm bandpass filter installed on an Axiovert 135 inverted epifluorescence microscope (Zeiss) 
connected to a Spex Industries Fluorolog system. Signals were normalised as described [175]. 
Islets transduced with R-GECO1 were starved for circa 30 minutes in a buffered solution 
containing 3 mM glucose, mounted in a Petri dish with Puramatrix Hydrogel and submerged 
in 2 ml of the buffer. Using a Leica SP5 system, confocal stacks were acquired every 15 
seconds for ten minutes. After two minutes, 1 ml of buffered solution containing 39 mM 
glucose was added to reach a concentration of 15 mM glucose. 
3.6.2 Static batch incubation 
Groups of 8-12 cultured islets were incubated at 37°C in different buffered solutions for 30 
minutes each. Following starvation (3 mM glucose), islets were incubated at low glucose (3 
mM) and subsequently high glucose (11 or 15 mM). Buffers were collected for insulin 
concentration measurements with AlphaLISA. Islets were collected in M-PER protein 
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extraction reagent (Thermo Fisher Scientific) for analysis of insulin content with AlphaLISA 
and/or DNA content by Quant-IT Picogreen dsDNA kit (Thermo Fisher Scientific). 
3.7 INTRAOCULAR TRANSPLANTATION OF ISLETS 
Islet transplantation was performed as previously described [176]. In brief, the mouse was 
anesthetised with a mixture of isoflurane (Baxter) and oxygen, placed on a heating pad and 
restrained by fixation of the head in a custom-made head holder. Anaesthesia was delivered 
through a gas mask (Figure 5). The eye was immobilised with forceps and the cornea was 
punctured with a 23-25 G needle from the side. Islets were loaded in the tip of a glass cannula 
attached via a polyethylene tubing to a 1 ml Hamilton syringe. Following insertion of the tip 
of the cannula via the puncture site, islets were transplanted into the anterior chamber of the 
eye. Temgesic (0.1 mg/kg) was given subcutaneously for post-operative analgesia. Mice 
were observed until complete recovery. Overview images of transplanted eyes were obtained 
using a digital camera connected to a Leica M60 stereomicroscope. 
3.8 FLUORESCENCE IMAGING OF ISLETS 
3.8.1 Microscopy settings 
Imaging was performed using a Leica TCS-SP2 or TCS-SP5 system equipped with Argon 
and HeNe lasers using 10x, 20x, 25x or 40x water-immersion objectives. Two-photon 
excitation was achieved using a Ti:Sapphire laser. Confocal stacks were acquired by 
reflection and fluorescence microscopy. While reflection microscopy is label-free, 
fluorescence microscopy requires fluorophores thereby allowing for the specific labelling of 
biological structures. Laser light is used to make optical sections in a plane of interest at a 
depth of up to a few hundred micrometres into the tissue at a subcellular resolution (<1 μm). 
The use of different laser lines for specific experiments is detailed in each paper. The step-
size between each optical section was 2 or 4 μm. Images were generally acquired at 8-bit 
with a resolution of 512 x 512 pixels. Scanning speed and laser intensities were adjusted to 
avoid any cellular damage to islets in vitro, and to the mouse eye or islet grafts in vivo.  
3.8.2 In vivo imaging of islets 
For in vivo imaging (Figure 5), mice were anesthetised with isoflurane as described above. 
Viscotears was used as an immersion medium between the lens and the mouse eye. Islet 
grafts were imaged between 1 week and 5 months after transplantation. Blood vessels were 
visualised by intravenous injection of 2.5 mg/ml dextran labelled with FITC or Texas Red 
(500 or 70 kDa, Invitrogen). 
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Figure 5: In vivo microscopy of islet grafts in the anterior chamber of the mouse eye.  
3.8.3 NAD(P)H and FAD imaging 
Nicotinamide adenine dinucleotide phosphate (NAD(P)H) and flavin adenine dinucleotide 
(FAD) are two endogenous fluorophores related to cellular metabolism occurring in the 
electron transport chain [177]. To image NAD(P)H and FAD, islet grafts were sequentially 
excited with a multiphoton laser at 760 nm and 900 nm, respectively. Signal was collected in 
a single plane at 12 bit with a resolution of 256 x 256 pixels using band-pass filters 460/50 
and 525/50 and a resonance scanner at 8000 Hz.  
3.8.4 In vivo intracellular Ca2+ imaging 
Imaging of GCaMP3 islet grafts was performed with female (Paper III) or male mice (Paper 
IV). Males were fasted for 4 hours in the morning or 12 hours overnight and anesthetised by 
intraperitoneal injection of 8 or 6 µl of a midazolam/fentanyl mixture per g bodyweight, 
respectively. Females were anesthetised unfasted with 8 µl per g bodyweight. One part of 
premixed fentanyl citrate (0.315 mg/ml) and fluanisone (10 mg/ml, VetaPlasma) was freshly 
mixed with two parts water and one part midazolam (5 mg/ml, Hameln). A tail vein catheter 
connected to a tubing containing 100 U/ml heparin in saline was installed. Blood glucose was 
measured directly before and after the recordings. While a single islet graft was continuously 
excited with a fluorescent lamp, GCaMP3 fluorescence was collected at 16 bit with a 
Hamamatsu camera installed on top of a 35°C heated microscope chamber. During a 15 or 
20-minutes recording, a piezo element under the control of LabVIEW software moved a 25x 
objective up and down every 2 s during which 60 images were collected, covering a xyz 
volume of 467 µm x 467 µm x 120 µm. After a 5-minute baseline a solution containing 
glucose (5%) or AVP (2 µM) was slowly (during 10 seconds) infused through the catheter at 
a dose of 4 µl per g bodyweight. 
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3.9 IMAGE ANALYSIS AND QUANTIFICATION 
3.9.1 Optical projection tomography 
Raw images obtained from optical projection tomography scanning underwent enhancement 
by applying a contrast limited adaptive histogram (CLAHE) algorithm with a 64 x 64 tile 
size as described before [178]. Tomographic reconstructions, made with NRecon v1.6.9.18 
software (SkyScan), were loaded into Imaris 7.7.0 (Bitplane) for beta cell volume 
quantification. Islets, defined as clusters of insulin positive voxels, were obtained by a 
manually set threshold. Debris or artefacts and objects smaller than 20,000 μm3 were 
removed, setting a detection threshold corresponding to spherical cell clusters of ~34 μm in 
diameter. Information on islet number and volume per pancreatic lobe was extracted. 
3.9.2 Backscatter-based islet volume 
AutoQuant X2 (Media Cybernetics) was used for deconvolution of confocal stacks acquired 
with the Leica SP2 system. No deconvolution was done for images acquired with the Leica 
SP5 system. Three different analysis protocols, each based on the backscatter signal, were 
used to quantify the volume of the islet graft. The islet volume in Paper I was calculated 
using Matlab (Mathworks) and defined as the equatorial volume which comprised 
backscatter positive signal from the top of the islet down to the equator. This script was found 
to work well for the analysis of islet growth over time. In Paper II the open source software 
Fiji [179] (version 1.50d or higher) was used to measure the projected area and perpendicular 
z-depth after applying the plugin Interactive Stack Rotation to line up the iris. Islet volume 
was calculated from the area and z-depth assuming the graft had the shape of half a sphere. 
This protocol was more accurate to quantify beta cell mass in shrinking islets. For Paper IV, 
the projected islet area was measured with Volocity and extrapolated to the volume of half a 
sphere. As demonstrated in Paper I, the projected area approximates the equatorial volume 
well and is a valid method to determine islet volumes when using large n-numbers. 
3.9.3 Functional measurements  
To analyse vessel volume and diameter, backscatter signal intensities, NAD(P)H/FAD ratio, 
beta cell size, and insulin or glucagon positive area, confocal images were loaded into 
Volocity (version 6.3, Perkin Elmer). Backscatter signal intensity was quantified for the 
whole islet (Paper I) or specifically in the beta cells of MIP-GFP islets exclusively using the 
signal that overlapped with the GFP signal while excluding dextran positive voxels (Paper 
IV). The only voxels included fell within a conical region of interest (ROI) with a diameter 
spanning 2/3 that of the islet and measuring 50 or 75 m into the islet from the top towards 
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the centre. The obtained average intensity was normalised by dividing with the intensity of 
the iris around the islet. Vessel volume was obtained by manual thresholding of the dextran 
positive signal within the islet volume. An average islet blood vessel diameter was obtained 
by measuring the diameter (based on dextran positive signal in a maximum projection view) 
in three random blood vessels. The average beta cell size per islet was determined by 
manually measuring the area of 10 GFP positive cells per MIP-GFP islet. Insulin and 
glucagon positive area were determined by manual thresholding.  
To analyse GCaMP3 recordings, Fiji software was used to obtain an average or maximum 
intensity projection for every two seconds of data. Each of the 450 or 600 time-frames was 
corrected for movement using the plug-in StackReg. The intensities over time were measured 
within the region of interest containing the islet. 
3.9.4 Transduction efficiency and cell death 
Transduction efficiency and islet cell apoptosis were determined as a percentage of the islet 
volume and calculated with Volocity. For each islet, the number of R-GECO1 or Annexin V 
Alexa Fluor 488 positive voxels was divided by the backscatter positive voxels by applying 
a manual threshold. Individual cells were automatically delineated within the R-GECO1 
positive voxels by applying local contrast adjustment and thresholding for structures with a 
volume of approximately 1000-1500 µm3. 
3.10 RNA ISOLATION AND QUANTITATIVE RT-PCR ANALYSIS 
Mouse iris containing single islet grafts was dissected in sterile ice-cold PBS. Using tweezers 
cleaned with RNaseZap (Thermo Fisher Scientific), a micro-biopsy was taken from single 
grafts and transferred to ice-cold lysis buffer. Biopsies were stored at -80°C until further 
processing using the Smart-seq2 protocol [180] to generate full length cDNA after RNA 
extraction. Quality of the obtained cDNA was verified using a High Sensitivity DNA 
Analysis Kit (Agilent Genomics) according to the manufacturer’s instructions. Expression of 
all genes was measured by quantitative real-time PCR using SYBR green (Life Technologies) 
and a QuantStudio 5 system (Thermo Fisher Scientific). Genes were normalised to 
porphobilinogen deaminase (PBGD). Due to an insufficient amount of material, protein 
levels could not be assessed. 
3.11 STATISTICAL ANALYSIS 
Data was processed using Excel (Microsoft). Statistical analyses were performed with Prism 
version 6.0 (GraphPad Software) using student’s unpaired and paired t-tests with a Holm-
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Sidak post-hoc test when appropriate, Mann-Whitney tests or one-way ANOVA. Data is 
presented as mean ± SD or SEM, or as median ± interquartile range, depending on the data 
distribution. Statistical significance was considered for P-values <0.05. Figures were 
assembled using Prism and Photoshop (Adobe).  
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4 RESULTS AND DISCUSSION 
4.1 DEVELOPMENT OF AN IMAGING METHOD TO STUDY BETA CELL MASS 
AND FUNCTION IN VIVO 
To visualise islets or beta cells at high resolution, laser scanning microscopy is often 
combined with fluorescently labelled cells, for instance from the transgenic MIP-GFP mouse 
[71, 161, 181]. However, unlabelled endocrine tissues can also be detected based on their 
reflective properties [182, 183]. 
4.1.1 Reflected light imaging permits label-free visualisation of islet 
morphology and quantification of islet volumes over time  
With reflected light microscopy, a beam of light is sent through an objective toward the islet, 
and photons that scatter backward at an angle of 180 degrees are collected via the same 
objective [184]. Reflected light imaging could be used to describe the 3D structure of islets 
isolated from mouse, rat and human using laser lines ranging from 458 nm up to 633 nm 
(Paper I, Figure 1), illustrating that islets exhibit similar reflective properties regardless of 
their origin or the wavelength used.  
To test if the backscatter signal could also be used to obtain precise morphological data from 
islet grafts, we transplanted islets into the ACE and performed in vivo reflected light 
microscopy. Processing of the acquired confocal slices with a custom-made Matlab script 
allowed the quantification of (1) the area in a 2D projection view, and (2) the equatorial 
volume, i.e. the volume of the islet measured from the top down to the equator, in a 3D 
reconstruction (Paper I, Figure 2). A good correlation was found when data on the projected 
area and the equatorial volume from a large number of islets were plotted against each other 
(Paper I, Figure 3), thus suggesting that one parameter could be used to describe the other 
in this model of beta cell mass expansion. Additionally, repeated imaging of the same islet 
grafts over time allowed the study of beta cell mass dynamics. 
To validate our islet mass analysis protocols, we turned to optical projection tomography 
(OPT) imaging, an established method to quantitatively assess beta cell mass ex vivo by 
exploiting whole-mount insulin staining and tissue clearing [145]. The same set of 
transplanted eyes was first imaged by reflected light microscopy and next collected and 
processed for OPT scanning. Accordingly, volumetric data was obtained from both 
modalities on the same islet grafts (Paper I, Figure 2). Although this data did not return the 
exact same volumes for individual grafts, likely due to changes in the ex vivo processing of 
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the samples, the ratios of single islet volumes were similar regardless of the imaging 
technique in use, validating backscatter intensity as a tool to accurately assess islet mass in 
vivo. 
4.1.2 Reflected light imaging reports on the secretory status of the islet 
As a side observation, longitudinal studies of ob/ob mice revealed that the development of 
insulin resistance was paralleled with a decrease backscatter signal in islet grafts [86]. Since 
the reason for this observation remained elusive, we decided to further investigate the light 
scattering properties of pancreatic islets. High resolution backscatter imaging illustrated that 
the punctate backscatter signal could be evenly detected in the cytoplasm of cells within the 
islet, but not in the nucleus (Paper I, Figure 1). Moreover, islets from hyperglycaemic mice 
were found to have significantly lower backscatter signal and insulin content (Paper I, Figure 
4). Together, these observations indicated that the source of reflection is housed within the 
cytoplasm at a high concentration but reduced in a milieu of insulin hypersecretion.  
It was hypothesised that the dense-core secretory granules within the beta cells (200-400 nm 
in diameter) were the main particles responsible for the strong light reflection based on the 
principle of Mie scattering, a phenomenon that applies to situations in which the size of the 
scattering particle is in the same range as the wavelength of light [185]. The hypothesis was 
tested by interfering with the formation of insulin crystals, a process that requires Zn2+ [18]. 
Indeed, treatment of islets with the Zn2+ chelator TPEN impeded insulin crystal formation as 
shown by electron microscopy. Furthermore, TPEN treated islets were found to have a 
decreased backscatter signal and lower uptake of the zinc-insulin crystal binding compound 
dithizone (Paper I, Figure 4). Although no direct changes in backscatter intensity could be 
monitored, our experiments demonstrate that the signal can be used as an intrinsic indicator 
for beta cell secretion in vitro and in vivo. 
4.2 GENERATION AND CHARACTERISATION OF A MOUSE MODEL OF 
MINIMAL BETA CELL MASS 
Changes in beta cell mass are a common feature in diabetes [186-188].  In vivo reflected light 
imaging was previously employed to monitor islet mass dynamics in models of obesity [86] 
and immune-mediated beta cell/islet destruction [163, 189]. However, despite being used 
extensively in diabetes research, surprisingly little data is available on the destruction kinetics 
of beta cell ablation models. To improve our understanding of the changes in beta cell mass 
in such models, we explored ablation mediated by diphtheria toxin (DT) and streptozotocin 
(STZ). 
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4.2.1 Loss in islet function precedes loss in islet mass in the RIP-DTR 
mouse model  
DT administered to RIP-DTR mice was previously shown to induce near-total beta cell 
ablation within two weeks, leading to the conversion of alpha cells into beta cells in the period 
thereafter [46]. Following a similar protocol, we treated RIP-DTR mice with DT and 
collected the pancreas after 15 days for OPT. Subsequent quantification showed that DT 
treated mice had lost ~90% of their pancreatic beta cell mass compared to vehicle treated 
controls (Paper II, Figure 1 and supplementary movie). To study the day-to-day kinetics of 
beta cell destruction in these mice, RIP-DTR islets were transplanted into the ACE and 
monitored longitudinally by reflected light microscopy. Whilst no changes could be observed 
in the control islets, RIP-DTR islet mass rapidly decreased after treatment with DT. The loss 
of beta cell mass found in the ACE after 15 days was similar to that observed in the pancreas 
by OPT (Paper II, Figure 2), thus confirming previous observations [86] that islets in the 
eye report on the status of islets in the pancreas. Moreover, the amount of mass that remained 
at 4 days post-DT was in line with previous findings in which the beta cell mass of the RIP-
DTR mouse was imaged using a bioluminescence approach [190].  
The gradual beta cell death, which was preceded by a robust inhibition of protein synthesis 
[191], led to a sharp rise in glycaemia between day two and three post-DT and was paralleled 
by a decrease in circulating insulin levels. Prior to the emergence of hyperglycaemia, around 
40 hours after treatment, RIP-DTR mice already presented impaired glucose intolerance 
(Paper II, Figure 3). At this point in time, when almost half the beta cell mass was lost, the 
remaining islet mass did not show any apparent morphological or ultrastructural changes 
although the insulin staining in the pancreas of RIP-DTR was found to be less homogeneous 
compared to controls (Paper II, Figure 4). The latter could be indicative of alterations in 
protein expression levels or insulin secretion. Intracellular Ca2+ experiments with isolated 
RIP-DTR islets as early as one day post-DT demonstrated functional defects in spite of a 
relatively intact morphology and insulin content (Paper II, Figure 5). These observations 
illustrate that in the RIP-DTR mouse islet function is lost prior to a substantial loss in islet 
mass. 
4.2.2 Streptozotocin treatment induced rapid hyperglycaemia and near total 
loss of pancreatic insulin content 
In a second model, beta cell loss was accomplished through the treatment with a single high 
dose of STZ. Repeated reflected light imaging of previously transplanted C57BL/6J mice 
illustrated a progressive decrease in islet mass upon STZ treatment (Figure 6), reminiscent 
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of the destruction kinetics seen in the RIP-DTR mice. Compared to DT treatment in RIP-
DTR mice, STZ caused a more abrupt hyperglycaemia in C57BL/6J mice, generally within 
hours (Paper III, Figure 2; Paper IV, Figure 1), underlining the different mechanism of 
action of the two toxins [45, 47]. One month after STZ treatment the pancreatic insulin 
content was almost negligible. 
 
Figure 6: Confocal images obtained from in vivo microscopy show an engrafted islet shrinking 
over time after streptozotocin treatment. Scale bar represents 100 µm. 
4.2.3 Combination of pancreatic beta cell ablation and islet transplantation 
creates a non-obese normoglycaemic model of minimal beta cell mass  
The studies on beta cell destruction kinetics in these two mouse models prompted us to 
investigate how much functional beta cell mass is minimally required to maintain 
normoglycaemia. Namely, it was postulated that a minimal number of beta cells would 
increase the workload on the individual beta cell. In our hands, titration experiments 
demonstrated that the intraocular “metabolic” transplantation of at least 75-100 islets was 
needed to revert hyperglycaemia in two-month-old STZ-treated C57BL/6J mice (hereafter 
referred to as the STZ + Tx model; Paper IV, Figure 1). However, recovery of 
hyperglycaemic RIP-DTR mice of approximately 5 months of age required a transplantation 
of 100-150 islets. Several factors can be designated to influence the number of islets needed 
for normalisation of glycaemia, including the quality and average size of donor islets, the age 
of the recipient, and the beta cell mass remaining in situ.  
Data on glycaemia, glucose tolerance and islet vascularisation obtained from the STZ + Tx 
model over time corroborated that engraftment was completed four weeks after the metabolic 
transplantation (Paper IV, Figures 1 and 2). Previous enucleation experiments performed 
after complete recovery immediately reverted hyperglycaemia [71], suggesting that the 
glucose homeostasis is maintained solely by the transplanted tissue. Furthermore, mice with 
a decreased beta cell mass were still able to efficiently handle a bolus of glucose despite 
lower circulating insulin levels, which could be explained by improved insulin sensitivity in 
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peripheral tissues (Paper IV, Figure 3). Thus, through pancreatic beta cell ablation with 
either STZ or DT and a subsequent metabolic transplantation of a minimal number of islets, 
two normoglycaemic and non-obese mouse models of decreased beta cell mass were 
established.  
4.3 DEVELOPMENT OF AN IN VIVO APPROACH TO ASSESS THE ROLE OF 
SPECIFIC GENES FOR BETA CELL FUNCTION 
To test the role of genes potentially involved in islet function, a beta cell specific expression 
methodology was developed. As a proof-of-concept we overexpressed the V1b receptor, a 
GPCR that is part of the vasopressin-oxytocin family and naturally expressed by beta cells at 
low levels [192, 193]. The choice for this receptor is twofold: Stimulation of the V1b receptor 
with its natural ligand AVP should elicit a direct mobilisation of [Ca2+]i in beta cells via the 
PLC pathway. Concomitantly, in vivo administration of AVP would lead to a transient 
increase in glycaemia due to vasopressin receptor mediated gluconeogenesis in the liver, 
thereby enabling us to test if our modified beta cells still maintained a proper glucose-
responsiveness.  
4.3.1 Improved virus-mediated gene transfer using pseudoislets 
To facilitate optimal gene transfer to all beta cells within the islets, we established a protocol 
in which dispersed islet cells in the presence of a virus were progressively reaggregated into 
pseudoislets, based on a previously pioneered method [194]. It was first confirmed that 
untransduced pseudoislets are functional in vitro and in vivo following transplantation into 
the ACE (Paper III, Figures 1 and 2). This is relevant as the pseudoislet formation requires 
temporary disruption of cell-cell contacts that are necessary for a proper islet function [7, 8, 
30, 195]. Our protocol proved superior to transduction of intact islets and could even be used 
to transduce human islet cells (Paper III, Supplementary Figures 3 and 4). While it exposed 
the cells to the virus for a relatively long period, substantially lower virus titres could be used 
thus benefitting cell survival (Paper III, Figure 3). 
4.3.2 Modulation of beta cell function by targeted overexpression of a GPCR 
To be able to monitor islet function in vivo we engineered pseudoislets from GCaMP3 islet 
cells. We overexpressed the V1b receptor specifically in beta cells, transplanted the islets 
into the ACE and monitored fluctuations in [Ca2+]i by real time fluorescent microscopy. As 
hypothesised, in vivo stimulation of pseudoislets with AVP acutely increased [Ca2+]i in beta 
cells (Paper III, Figure 5). These results demonstrate that our expression methodology can 
be used to successfully modulate beta cell function by artificially modifying intracellular 
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pathways. Additionally, intravenous administration of AVP led to a gradual rise in glycaemia 
and consequently a secondary increase in [Ca2+]i in beta cells, indicating that their glucose 
sensing mechanism remained intact. The current imaging protocol, just like a recently 
published setup by Chen and co-workers [124], enables the monitoring of changes in beta 
cell function in vivo. However, whereas their protocol is limited to single plane scanning, our 
protocol comes with the advantage that it uses GCaMP3 signal from the whole islet. 
Furthermore, the proof-of-concept experiments regarding the overexpression of the V1b 
receptor illustrate how our approach can be exploited to assess the role of specific genes for 
beta cell function. 
4.4 INVESTIGATION OF CHANGES IN BETA CELL FUNCTION IN VIVO 
Beta cells possess a natural ability to adapt their functional capacity [79]. To study the process 
of beta cell plasticity, we and others have recently utilised mouse models of obesity and 
insulin resistance [86, 115, 124, 126]. These mice have augmented circulating glucose and 
free fatty acid levels, both known regulators of islet function [196], making it difficult to 
identify other factors and pathways which can independently regulate beta cell function. To 
circumvent this and study adaptations in beta cells under normoglycaemic and non-obese 
circumstances, we employed our previously developed STZ + Tx model. These mice, and 
controls with an intact endocrine pancreas, received 5-10 reporter islets in their ACE (Paper 
IV, Figure 1). 
4.4.1 Decrease in overall beta cell mass increases beta cell workload 
To verify that we could increase the functional capacity of individual beta cells by decreasing 
the total amount of beta cells, we combined the information of several parameters. Based on 
measurements of beta cell mass decay and pancreatic insulin content, as well as the 
volumetric analysis of a graft consisting of 75-100 islets, it was estimated that STZ + Tx mice 
had a total beta cell mass comprising 20-50% the mass of controls. However, their circulating 
insulin levels were approximately one-thirds lower (Paper IV, Figure 3). Hence, it could be 
expected that the beta cells in the STZ + Tx model were pressured to perform at their maximal 
capacity to maintain normoglycaemia. Indeed, individual beta cells exhibited a transiently 
decreased light scattering phenotype suggestive of insulin hypersecretion, thus confirming 
an increased workload. 
  33 
4.4.2 Increased insulin demand accelerates islet engraftment and causes 
beta cell hypertrophy 
To study the effect of an increased beta cell workload on the engraftment process, islets were 
imaged at 1, 2 and 4 weeks after transplantation. Surprisingly, while the islets comprised the 
same range of sizes upon transplantation, quantification of their islet volume one week later 
showed that islets under high workload were significantly larger than islets transplanted in 
control mice. The increase in intraislet vessel volume, vessel diameter and the beta cell size 
found in islets in the high workload group could explain this difference (Paper IV, Figure 
2). Beta cell hypertrophy has also been found in other conditions of high workload [86, 115, 
136]. Although all islets are completely revascularised after four weeks, data from week 1 
and 2 post-transplantation suggests that engraftment is accelerated in islets under high insulin 
demand. To our knowledge, no other studies have observed (or studied) differences in 
revascularisation under similar circumstances. However, similar studies investigating islets 
transplanted under hyperglycaemic conditions and in different locations did not detect any 
changes in revascularisation speed [197, 198]. 
4.4.3 Beta cells under high workload display functional adaptations in vivo 
Beta cells were characterised in more detail after one month of exposure to high workload, 
when islet engraftment was completed. In vivo [Ca2+]i recordings using Ins-GCaMP3 islets 
and NAD(P)H/FAD imaging suggested that beta cell metabolism was higher under basal 
conditions (Paper IV, Figure 4). This is in line with observations using HFD fed animals 
[124, 164]. In addition, while high glucose stimulation did not produce any differences in the 
amplitude of the [Ca2+]i response, the timing of response was faster in islets that had been 
exposed to high workload compared to controls (Paper IV, Figure 4). The former result 
demonstrates that in our in vivo model beta cells remain functional after long-term exposure 
to high workload and do not precipitate failure within this time span. The latter finding, in 
combination with the lower glycaemia after 6 hours fasting (Paper IV, Figure 3), suggests a 
left-shifted or steeper sigmoidal curve with regards to glucose sensitivity and lowering of the 
glucose threshold. Hypersensitivity for glucose appears to be a common adaptive mechanism 
of beta cells in response to high workload as it was observed in several animal models [110, 
125, 132, 135] including a similar STZ + Tx model [199]. 
4.5 IDENTIFICATION OF GENES INVOLVED IN THE NATURAL REGULATION 
OF BETA CELL FUNCTION 
In pursuit of a mechanism that could explain the changes in beta cell function, we established 
a method that enabled gene expression analysis in single islet grafts. Our protocol was based 
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on a recently developed procedure for single cells [180] and involved the collection of RNA 
from an islet microbiopsy followed by the preparation of cDNA (Paper IV, Figure 5). 
Accordingly, we could compare differences in gene expression levels between individual 
grafts. Importantly, islet cells were spared from enzymatic digestion, yet an extra step that 
may affect the outcome in an already precarious procedure [200]. 
4.5.1 Upregulation of glucokinase is a natural adaptive response to improve 
beta cell function 
In our preliminary analysis, while no differences were detected in the levels of insulin or 
glucose transporters, a twofold upregulation in glucokinase (GCK) mRNA was found in islets 
exposed to a month of high workload compared to control grafts (Paper IV, Figure 5). It is 
likely that the higher mRNA levels would translate into increased GCK activity, although 
this was not assessed at this stage. Since the processing of glucose by the GCK enzyme is 
thought to be a rate-limiting step in beta cell metabolism [201], this result is in agreement 
with our hypothesis that beta cells under high workload increase their functional capacity. In 
line with our results, two other studies found enhanced GCK activity in the islets of rats after 
partial pancreatectomy [131, 133]. Furthermore, mutations in the GCK gene (e.g. MODY2) 
result in various diabetic phenotypes in human subjects [202]. The current findings underpin 
the importance of GCK in the maintenance of a functional beta cell mass.  
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5 CONCLUSIONS AND OUTLOOK 
The adaptive capacity of the beta cell is of paramount importance for the maintenance of a 
normal blood glucose homeostasis. Although quite some research has focused on the 
mechanisms behind compensatory beta cell expansion, our knowledge about the regulation 
of beta cell function remains poor, likely due to technical limitations. In this thesis work, we 
overcame some of these limitations through the development of several technical 
innovations, thereby allowing us to shed new light on the mechanisms underlying functional 
beta cell plasticity. The outcomes are graphically summarised in Figure 7. 
 
Figure 7: Graphical abstract of the papers included in this thesis. 
We established a label-free method to non-invasively study changes in beta cell mass and 
function in the same islet over time by performing reflected light microscopy of endocrine 
tissues transplanted into the anterior chamber of the mouse eye. We developed analysis 
protocols that used the backscattered light signal to precisely quantify the volume and 
secretory status of single islet grafts (Paper I). Implementing our imaging approach allowed 
us to, for the first time, describe in detail the morphological changes in islets mass kinetics 
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in two commonly used mouse models of beta cell loss, the RIP-DTR mouse (Paper II) and 
the STZ-treatment model. Our findings from the combined measurements of islet mass and 
beta cell function illustrate that for accurate staging and diagnosis of diabetes it is of 
importance to monitor both parameters. During the last years, several research groups and 
consortia have attempted to broaden the possibilities to non-invasively image beta cells in a 
(pre-)clinical setting [138, 203]. Although our confocal microscopy-based approach to 
visualise beta cells in vivo has some inherent limitations e.g. owing to the poor tissue 
penetration, its application for humans is not unthinkable. Recently, Diez and colleagues 
modified the ACE platform for rodents and successfully imaged autologous islet grafts in the 
ACE of non-human primates [14]. 
We generated a mouse model of minimal beta cell mass through a combination of pancreatic 
beta cells ablation and a metabolic transplantation into the ACE (Paper IV). In conjunction 
with other observations [204], the results presented in this thesis demonstrate that relatively 
few islets are needed to re-establish a normal glucose homeostasis in mice. Hence, it is not 
necessary to replenish the initial beta cell mass completely. If this also holds true for human 
subjects is unclear. Most individuals can undergo partial (<50%) pancreatectomy without 
detrimental consequences for their blood glucose homeostasis [205], suggesting that humans, 
like rodents, also have some overcapacity regarding their functional beta cell mass. Yet, the 
“Edmonton protocol” prescribes the transplantation of at least 11,000 islet equivalents per kg 
into the portal vein to treat T1D individuals [65]. Such high numbers may not be required in 
a more islet-friendly transplantation site like the ACE, where the tissue is not hampered by 
for example immediate blood-mediated immune reactions. In line with this, it could be 
envisioned that the anterior segment of the human eye, despite harbouring limited space for 
islets, remains a feasible transplantation site for clinical islet transplantations. 
We developed an approach to test the role of specific proteins in the regulation of beta cell 
function. As a proof-of-concept, we synthetically overexpressed a particular GPCR and could 
subsequently regulate islet graft function through stimulation of an amplifying pathway in 
beta cells (Paper III). Although the activation of specific GPCRs on the beta cell is a 
common pharmacological approach for T2D [26], it has been shown that GPCR expression 
decreases under diabetic conditions [206, 207]. Our beta cell specific expression 
methodology can, perhaps in combination with more stable viruses and a synthetically 
designed GPCR such as described by Guettier et al. [208], be used as a novel approach in the 
regulation of islet graft function.  
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We could increase the workload of individual beta cells by decreasing the overall beta cell 
mass. Islets transplanted under high workload conditions engrafted faster in terms of 
revascularisation. Moreover, their beta cells underwent several functional changes over the 
course of one month such as hypertrophy, hypersecretion of insulin, and hypersensitivity to 
glucose. It was concluded that mouse beta cells can display functional plasticity under non-
obese and normoglycaemic circumstances. Our preliminary data suggests that the 
upregulation of GCK levels and/or activity is a natural adaptive response of beta cells to 
improve their function (Paper IV). As such, our findings in mice help to explain the 
phenotype of humans with mutations in the GCK gene (i.e. MODY2). Furthermore, in line 
with previous research, our results suggest that GCK is a potential target for future diabetes 
therapies. One approach that has gained momentum over the past few years is to 
pharmacologically target endogenous beta cells and activate GCK. So far, a number of 
synthetic compounds that influence GCK or its proposed activator 6PF2K/Fru2,6-P2ase have 
been successfully developed and evaluated, albeit without direct clinical potential [202]. Of 
course, our pseudoislet procedure can also be used to genetically engineer beta cells to make 
them express more (efficient) GCK. To identify more genes and pathways involved in the 
mechanisms behind beta cell adaptation, next generation sequencing technologies can be 
applied.  
In a more distant future one could envision that our synthetic biology procedure becomes an 
integral part of the clinical islet transplantation process. To successfully cure diabetes, 
patients would be transplanted with tailor-made islets that are engineered to have a superior 
quality and survival, and resist immune-mediated attacks. In such a scheme, GPCRs and 
GCK are just two examples of candidate proteins that can be modulated to improve islet 
function.  
In conclusion, using our newly established tools to assess and improve beta cell function in 
vivo, we were able to perform a comprehensive and unparalleled functional phenotyping of 
beta cells in the living organism. The technical innovations and biological mechanisms 
presented in this thesis contribute to greater efforts in the field of diabetes research aiming to 
advance diagnostics and therapeutics.  
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